# US 2019/0376969 A1 · Nasopharyngeal protein biomarkers of acute respiratory virus infection and methods of using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376969 A1
- Document ID: US20190376969A1
- Status: Published application
- Kind: A1
- Application number: 16/483,113
- Filed: 2018-02-02
- Published: 2019-12-12
- Earliest claimed: 2017-02-03
- Assignees: Duke University
- Applicants: Duke University
- Inventors: Thomas W. Burke; Ricardo Henao Giraldo; Erik Soderblom; Joseph Lucas; Christopher W. Woods; Geoffrey S. Ginsburg
- Web page: https://patentgrep.com/patent/US20190376969A1

## CPC

- A61K 31/00: Medicinal preparations containing organic active ingredients
- G01N 33/56983: {Viruses}
- C07K 14/005: from viruses
- G01N 33/577: involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)}
- G01N 2333/005: from viruses
- G01N 2333/095: Rhinovirus
- G01N 2333/11: Orthomyxoviridae, e.g. influenza virus
- G01N 2333/135: Respiratory syncytial virus
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides methods for determining the presence or absence of and/or the etiology of an acute respiratory viral infection in a subject, as well as methods of treating the subject based on the determination, by measuring on a platform the expression levels of a pre-defined set of gene products.

## Claims

### Claim 1

A method for making an acute respiratory viral (ARV) illness classifier for a platform, said method comprising:
(a) obtaining biological samples from a plurality of subjects known to be suffering from an ARV illness;
(b) measuring on said platform the expression levels of a plurality of pre-defined gene products in each of said biological samples from step (a);
(c) normalizing the gene product expression levels obtained in step (b) to generate normalized expression values; and
(d) generating an ARV illness classifier for the platform based upon said normalized gene product expression values, to thereby make the ARV illness classifier for the platform.

### Claim 2 (depends on 1)

The method according to claim 1 in which the measuring comprises, or is preceded by, one or more steps of: purifying cells, cellular materials, or secreted materials from said sample, preserving or disrupting the cells or cellular materials of said sample, and reducing complexity of sample through isolating or fractionating gene products from said sample.

### Claim 3 (depends on 1)

The method according to claim 1 in which the measuring comprises quantitative or semi-quantitative direct detection or indirect detection using analyte specific reagents or methods.

### Claim 4 (depends on 3)

The method according to claim 3, in which the analyte specific reagents are selected from the group consisting of antibodies, antibody fragments, aptamers, peptides and combinations thereof.

### Claim 5 (depends on 1)

The method according to claim 1 in which the platform is selected from the group consisting of an array platform, a gene product analyte hybridization or capture platform, multi-signal coded detector platform, a mass spectrometry platform, an amino acid sequencing platform, or a combination thereof

### Claim 6 (depends on 1)

The method according to claim 1 in which the generating comprises iteratively:
(i) assigning a weight for each normalized gene product expression value, entering the weight and expression value for each gene product into a classifier equation and determining a score for outcome for each of the plurality of subjects, then
(ii) determining the accuracy of classification for each outcome across the plurality of subjects, and then
(iii) adjusting the weight until accuracy of classification is optimized to provide said viral ARI for the platform, wherein analytes having a non-zero weight are included in the respective classifier, and optionally uploading components of each classifier (gene product analytes, weights and/or etiology threshold value) onto one or more databases.

### Claim 7 (depends on 6)

The method according to claim 6 in which the classifier is a linear regression classifier and said generating comprises converting a score of said classifier to a probability.

### Claim 8 (depends on 1)

The method as in claim 1 in which the method further comprises validating said ARV illness classifier against a known dataset comprising at least two relevant clinical attributes, and optionally determining a threshold for the determination of ARV illness.

### Claim 9 (depends on 1)

The method as in claim 1 in which the ARV illness classifier or a subset thereof comprises expression levels of from 1, 5, 8, or 10 to 15, 20, 25 or 26 of the gene products listed in Table 2/2A, and optionally wherein the classifier has a negative predictive value of greater than 90%.

### Claim 10 (depends on 9)

The method according to claim 9 in which the plurality of pre-defined gene products comprises from 1, 5, 8, or 10 to 15, 20, 25 or 26 proteins and/or component peptides/epitopes listed in Table 2/2A or Table S4.

### Claim 11

A method for determining the presence of a respiratory virus in a subject or for determining the viral etiology of an acute respiratory viral (ARV) illness in a subject suffering therefrom, comprising:
(a) obtaining a biological sample from the subject;
(b) measuring on a platform expression levels of a pre-defined set of gene products in said biological sample;
(c) normalizing the gene product expression levels to generate normalized expression values;
(d) entering the normalized gene product expression values into one or more acute respiratory virus (ARV) illness classifiers, said classifier(s) comprising pre-defined weighting values for each of the gene products of the pre-determined set of proteins and/or peptides for the platform, optionally wherein said classifier(s) are retrieved from one or more databases; and
(e) calculating a presence or an etiology probability for one or more of the ARV illness based upon said normalized expression values and said classifier(s), and optionally determining a threshold for the determination of ARV illness,
to thereby determine the presence of a respiratory virus in the subject or the viral etiology of an ARV illness in the subject.

### Claim at position 12

12-13. (canceled)

### Claim 14

A method for determining whether a subject is at risk of developing an ARV illness, or for determining the presence of a latent or subclinical respiratory viral infection in a subject exhibiting no symptoms, comprising:
(a) obtaining a biological sample from the subject;
(b) measuring on a platform expression levels of a pre-defined set of gene products in said biological sample;
(c) normalizing the gene product expression levels to generate normalized expression values;
(d) entering the normalized gene product expression values into one or more acute respiratory virus illness classifiers, said classifier(s) comprising pre-defined weighting values for each of the gene products of the pre-determined set of proteins and/or peptides for the platform, optionally wherein said classifier(s) are retrieved from one or more databases; and
(e) calculating a risk probability or a probability for one or more of an ARV illness based upon said normalized expression values and said classifier(s), and optionally determining a threshold for the determination of ARV illness, to thereby determine whether the subject is a risk of developing an ARV illness, or to determine the presence of a latent respiratory viral infection in the subject.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The method as in claim 14 in which the method further comprises:
(f) comparing the probability to pre-defined thresholds, cut-off values, or ranges of values that indicate an infection or a likelihood of infection.

### Claim 17 (depends on 14)

The method as in claim 14 in which the gene product is selected from the group consisting of proteins, component peptides, expressed proteome, epitopes or subset thereof and combinations thereof

### Claim 18 (depends on 14)

The method as in claim 14 in which the subject is suffering from acute respiratory virus illness symptoms or the subject is suspected of having a viral infection.

### Claim 19 (depends on 14)

The method as in claim 14 in which a combined host protein or peptide viral ARI classifier is combined or measured in parallel with pathogen detection from said samples.

### Claim 20 (depends on 14)

The method as in claim 14 in which the method further comprises generating a report assigning the subject a score indicating the probability of the presence and/or etiology of the acute respiratory illness.

### Claim 21 (depends on 14)

The method as in claim 14 20 in which the etiology of the AVR illness comprises a respiratory virus.

### Claim 22 (depends on 21)

The method according to claim 21 in which the AVR illness is selected from the group consisting of, but not limited to, human rhinovirus (HRV), respiratory syncytial virus (RSV), influenza, and combinations thereof.

### Claim 23 (depends on 14)

The method as in claim 14 in which the pre-defined set of gene products comprises from 1, 5, 8, or 10 to 15, 20, 25 or 26 gene products.

### Claim 24 (depends on 23)

The method according to claim 23 in which the pre-defined set of gene products comprises from 1, 5, 8, or 10 to 15, 20, 25 or 26 proteins and/or component peptides listed in Table 2/2A or Table S4, and optionally wherein the classifier has a negative predictive value of greater than 90%.

### Claim 25 (depends on 14)

The method as in claim 14 in which the biological sample is selected from the group consisting of peripheral blood, sputum, nasal or nasopharyngeal swab, nasopharyngeal lavage, bronchoalveolar lavage, endotracheal aspirate, respiratory expectorate, respiratory epithelial cells or tissue, or other respiratory cell, tissue, or secretion samples and combinations thereof.

### Claim 26 (depends on 25)

The method according to claim 25 in which the biologic sample is obtained as a nasal or respiratory spray captured onto paper-based matrix for extraction or direct assay.

### Claim 27 (depends on 1)

An ARV illness classifier obtained according to the method as in claim 1, optionally wherein the classifier has a negative predictive value of greater than 90%.

### Claim 28 (depends on 14)

A method of treating comprising administering to the subject an appropriate treatment regimen based on an etiology determined by a method according to claim 14.

### Claim 29 (depends on 28)

The method according to claim 28 in which the appropriate treatment regimen comprises an antiviral therapy.

### Claim 30 (depends on 14)

A method of monitoring response to a vaccine, drug or other antiviral therapy in a subject suffering from, or at risk of developing, an acute respiratory viral illness comprising determining a host response of said subject using a method according claim 14.

### Claim 31 (depends on 30)

The method according to claim 30 in which the drug is an antiviral drug.

### Claim 32

A system for determining the presence of and/or determining an etiology of an acute respiratory viral illness in a subject comprising:
(i) at least one processor;
(ii) a sample input circuit configured to receive a biological sample from the subject;
(iii) a sample analysis circuit coupled to the at least one processor and configured to determine gene product expression levels of the biological sample;
(iv) an input/output circuit coupled to the at least one processor;
(v) a storage circuit coupled to the at least one processor and configured to store data, parameters, and/or classifiers; and
(vi) a memory coupled to the processor and comprising computer readable program code embodied in the memory that when executed by the at least one processor causes the at least one processor to perform operations comprising:
(a) controlling/performing measurement via the sample analysis circuit of protein and/or peptide expression levels of a pre-defined set of gene products in said biological sample;
(b) normalizing the gene product expression levels to generate normalized gene product expression values; retrieving from the storage circuit an ARV classifier, said classifier(s) comprising predefined weighting values for each of the pre-defined set of gene products;
(c) entering the normalized gene product expression values into one or more acute respiratory viral illness classifiers selected from the ARV classifier;
(d) calculating a presence and/or etiology probability for an ARV illness based upon said classifier(s), and optionally determining a threshold for the determination of ARV illness; and
(e) controlling output via the input/output circuit of a determination of the presence of, or the etiology of, the acute respiratory viral illness in the subject.

### Claim 33 (depends on 32)

The system according to claim 32 in which the system comprises computer readable code to transform quantitative, or semi-quantitative, detection of gene product expression to a cumulative score or probability of the etiology of the ARV illness.

### Claim 34 (depends on 32)

The system according to claim 32 in which the system comprises an array platform, a gene product analyte hybridization or capture platform, multi-signal coded detector platform, a mass spectrometry platform, an amino acid sequencing platform, or a combination thereof.

### Claim 35 (depends on 32)

The system according to claim 32 in which the pre-defined set of gene products comprises from 1-26 gene products.

### Claim 36 (depends on 35)

The system according to claim 35 in which the pre-defined set of analytes comprises from 1, 5, 8, or 10 to 15, 20, 25 or 26 proteins and/or component peptides/epitopes listed in Table 2/2A or Table S4, and optionally wherein the classifier has a negative predictive value of greater than 90%.

### Claim 37

A method for determining the presence or absence of a respiratory virus in a population of subjects comprising, consisting of, or consisting essentially of:
(a) obtaining a biological sample from each of the subjects;
(b) measuring on a platform expression levels of a pre-defined set of gene products in each of the biological samples;
(c) normalizing the gene product expression levels to generate normalized expression values;
(d) entering the normalized gene product expression values into one or more acute respiratory virus illness classifiers, said classifier(s) comprising pre-defined weighting values for each of the gene products of the pre-determined set of proteins and/or peptides for the platform, optionally wherein said classifier(s) are retrieved from one or more databases; and
(e) calculating presence probability for an ARV illness based upon said normalized expression values and said classifier(s), to thereby determine the presence or absence of a respiratory virus in the population of subjects.

### Claim 38 (depends on 37)

The method of claim 37, wherein the method comprises determining a threshold for the determination of ARV illness, optionally where said threshold is suitable for ruling out the presence of a viral infection, and/or wherein the method further comprises administering an antiviral treatment to subject(s) that have been determined to have an acute viral infection.

### Claim at position 38

39-41. (canceled)

### Claim 42

A method for determining whether an antibacterial therapy should administered to a subject suffering from a respiratory infection comprising, consisting of, or consisting essentially of:
(a) obtaining a biological sample from the subject;
(b) measuring on a platform expression levels of a pre-defined set of gene products in said biological sample;
(c) normalizing the gene product expression levels to generate normalized expression values;
(d) entering the normalized gene product expression values into one or more acute respiratory virus (ARV) illness classifiers, said classifier(s) comprising pre-defined weighting values for each of the gene products of the pre-determined set of proteins and/or peptides for the platform, optionally wherein said classifier(s) are retrieved from one or more databases;
(e) calculating presence probability for one or more ARV illnesses based upon said normalized expression values and said classifier(s), to thereby determine the presence of a respiratory virus infection in the subject; and
(f) not administering to the subject an antibacterial therapy if the presence of a respiratory virus is determined.

### Claim 43

A kit for determining the presence or absence of viral etiology of an ARV illness in a subject, or for detecting the presence or absence of a respiratory virus in a subject, comprising:
(a) a means for extracting a biological sample;
(b) a means for generating one or more arrays consisting of a plurality of antibodies or other analyte specific reagents for use in measuring gene product expression levels of a pre-defined set of gene products; and
(c) optionally, instructions for use.

### Claim 44

(canceled)
